QQQ   443.86 (-0.22%)
AAPL   171.47 (-1.06%)
MSFT   420.25 (-0.28%)
META   487.97 (-1.19%)
GOOGL   150.76 (-0.07%)
AMZN   180.24 (+0.23%)
TSLA   176.61 (-1.79%)
NVDA   902.47 (+0.00%)
NIO   4.53 (-3.00%)
AMD   180.18 (+0.33%)
BABA   72.46 (+1.22%)
T   17.68 (+0.74%)
F   13.23 (+1.30%)
MU   117.55 (-1.33%)
CGC   9.10 (-4.71%)
GE   175.00 (-2.84%)
DIS   122.57 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.06 (+1.01%)
PYPL   67.21 (+0.96%)
XOM   116.07 (+0.96%)
QQQ   443.86 (-0.22%)
AAPL   171.47 (-1.06%)
MSFT   420.25 (-0.28%)
META   487.97 (-1.19%)
GOOGL   150.76 (-0.07%)
AMZN   180.24 (+0.23%)
TSLA   176.61 (-1.79%)
NVDA   902.47 (+0.00%)
NIO   4.53 (-3.00%)
AMD   180.18 (+0.33%)
BABA   72.46 (+1.22%)
T   17.68 (+0.74%)
F   13.23 (+1.30%)
MU   117.55 (-1.33%)
CGC   9.10 (-4.71%)
GE   175.00 (-2.84%)
DIS   122.57 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.06 (+1.01%)
PYPL   67.21 (+0.96%)
XOM   116.07 (+0.96%)
QQQ   443.86 (-0.22%)
AAPL   171.47 (-1.06%)
MSFT   420.25 (-0.28%)
META   487.97 (-1.19%)
GOOGL   150.76 (-0.07%)
AMZN   180.24 (+0.23%)
TSLA   176.61 (-1.79%)
NVDA   902.47 (+0.00%)
NIO   4.53 (-3.00%)
AMD   180.18 (+0.33%)
BABA   72.46 (+1.22%)
T   17.68 (+0.74%)
F   13.23 (+1.30%)
MU   117.55 (-1.33%)
CGC   9.10 (-4.71%)
GE   175.00 (-2.84%)
DIS   122.57 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.06 (+1.01%)
PYPL   67.21 (+0.96%)
XOM   116.07 (+0.96%)
QQQ   443.86 (-0.22%)
AAPL   171.47 (-1.06%)
MSFT   420.25 (-0.28%)
META   487.97 (-1.19%)
GOOGL   150.76 (-0.07%)
AMZN   180.24 (+0.23%)
TSLA   176.61 (-1.79%)
NVDA   902.47 (+0.00%)
NIO   4.53 (-3.00%)
AMD   180.18 (+0.33%)
BABA   72.46 (+1.22%)
T   17.68 (+0.74%)
F   13.23 (+1.30%)
MU   117.55 (-1.33%)
CGC   9.10 (-4.71%)
GE   175.00 (-2.84%)
DIS   122.57 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.06 (+1.01%)
PYPL   67.21 (+0.96%)
XOM   116.07 (+0.96%)
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

$37.80
+0.91 (+2.47%)
(As of 01:58 PM ET)
Today's Range
$36.95
$38.49
50-Day Range
$36.08
$49.54
52-Week Range
$33.79
$63.57
Volume
599,050 shs
Average Volume
1.41 million shs
Market Capitalization
$4.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.44

10x Genomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
65.2% Upside
$62.44 Price Target
Short Interest
Bearish
7.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.71mentions of 10x Genomics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$773,766 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.47) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.46 out of 5 stars

Medical Sector

139th out of 939 stocks

Analytical Instruments Industry

6th out of 28 stocks

TXG stock logo

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Stock Price History

TXG Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
TXG Nov 2024 40.000 put
TXG Aug 2024 60.000 call
TXG Dec 2024 40.000 put
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
TXG Apr 2024 60.000 call
TXG Apr 2024 40.000 put
TXG Mar 2024 30.000 call
Q4 2023 10X Genomics Inc Earnings Call
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,259
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$62.44
High Stock Price Target
$75.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+66.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-255,100,000.00
Pretax Margin
-40.21%

Debt

Sales & Book Value

Annual Sales
$618.73 million
Book Value
$6.22 per share

Miscellaneous

Free Float
106,476,000
Market Cap
$4.47 billion
Optionable
Optionable
Beta
1.93
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 47)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 49)
    Co-Founder, President, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 48)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 57)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Manager of Investor Relations and Strategic Finance
  • Ms. Rebecca Port
    Chief People Officer
  • Mr. James Bryant
    Director of Legal
  • Mr. Nikhil Rao
    Director of Product Management
  • Mr. Florian Baumgartner
    Senior Product Manager

TXG Stock Analysis - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings
or view top-rated stocks.

What is 10x Genomics' stock price target for 2024?

9 Wall Street research analysts have issued twelve-month target prices for 10x Genomics' stock. Their TXG share price targets range from $54.00 to $75.00. On average, they anticipate the company's share price to reach $62.44 in the next twelve months. This suggests a possible upside of 65.2% from the stock's current price.
View analysts price targets for TXG
or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2024?

10x Genomics' stock was trading at $55.96 at the start of the year. Since then, TXG shares have decreased by 32.5% and is now trading at $37.80.
View the best growth stocks for 2024 here
.

Are investors shorting 10x Genomics?

10x Genomics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 8,580,000 shares, an increase of 24.5% from the February 29th total of 6,890,000 shares. Based on an average daily trading volume, of 1,360,000 shares, the short-interest ratio is presently 6.3 days.
View 10x Genomics' Short Interest
.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TXG earnings forecast
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) issued its quarterly earnings results on Thursday, February, 15th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.05. The firm had revenue of $183.98 million for the quarter, compared to analyst estimates of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative trailing twelve-month return on equity of 28.82%. The company's revenue was up 17.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.15) EPS.

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $702.1 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

10x Genomics (TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.62%), Vanguard Group Inc. (7.56%), Baillie Gifford & Co. (6.70%), ARK Investment Management LLC (3.42%), Sands Capital Management LLC (3.04%) and Brown Capital Management LLC (2.98%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXG) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners